MA55467A - Utilisations thérapeutiques de dulaglutide - Google Patents
Utilisations thérapeutiques de dulaglutideInfo
- Publication number
- MA55467A MA55467A MA055467A MA55467A MA55467A MA 55467 A MA55467 A MA 55467A MA 055467 A MA055467 A MA 055467A MA 55467 A MA55467 A MA 55467A MA 55467 A MA55467 A MA 55467A
- Authority
- MA
- Morocco
- Prior art keywords
- dulaglutide
- therapeutic uses
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829717P | 2019-04-05 | 2019-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55467A true MA55467A (fr) | 2022-02-09 |
Family
ID=68732046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055467A MA55467A (fr) | 2019-04-05 | 2019-11-04 | Utilisations thérapeutiques de dulaglutide |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11890325B2 (fr) |
| EP (1) | EP3946428A1 (fr) |
| KR (3) | KR20250005518A (fr) |
| CN (3) | CN114732897A (fr) |
| AU (2) | AU2019439626B2 (fr) |
| BR (1) | BR112021017315A2 (fr) |
| CA (2) | CA3177693A1 (fr) |
| EA (1) | EA202192296A1 (fr) |
| IL (2) | IL325089A (fr) |
| MA (1) | MA55467A (fr) |
| MX (1) | MX2021012177A (fr) |
| SG (1) | SG11202109892UA (fr) |
| TW (3) | TW202525321A (fr) |
| UA (1) | UA128791C2 (fr) |
| WO (1) | WO2020204998A1 (fr) |
| ZA (1) | ZA202106250B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020190591A1 (fr) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Formulations conservées |
| CA3223313A1 (fr) | 2021-06-23 | 2022-12-29 | Eli Lilly And Company | Methodes d'utilisation et compositions comprenant un analogue d'incretine |
| WO2025222169A1 (fr) | 2024-04-19 | 2025-10-23 | Faraday Pharmaceuticals, Inc. | S-oxprénolol destiné à préserver la masse musculaire, la densité osseuse et la fonction cardiaque dans des traitements de perte de poids |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503963A (ja) | 1996-02-06 | 2001-03-27 | イーライ・リリー・アンド・カンパニー | 糖尿病治療 |
| JP4716641B2 (ja) | 2000-06-16 | 2011-07-06 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド−１類似体 |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US20040209803A1 (en) | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| DK1831252T3 (da) | 2004-12-22 | 2009-10-05 | Lilly Co Eli | GLP-1 analog fusionsproteinformuleringer |
| ATE499088T1 (de) | 2007-07-10 | 2011-03-15 | Lilly Co Eli | Glp-1-fc fusionsprotein-formulierung |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| EP3895724B1 (fr) | 2013-05-22 | 2025-06-25 | Zensun (Shanghai) Science and Technology, Co., Ltd. | Libération prolongée de neuréguline pour le traitement de l'insuffisance cardiaque |
| WO2015013762A1 (fr) | 2013-07-29 | 2015-02-05 | Sg Ventures Pty Limited | Pigments métalliques et procédé de revêtement d'un substrat métallique |
| CN108883158A (zh) | 2016-03-04 | 2018-11-23 | 诺和诺德股份有限公司 | 用于肾脏病况的利拉鲁肽 |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| SI3275438T1 (sl) * | 2016-07-29 | 2021-05-31 | Kowa Company, Ltd. | Metode preprečevanja kardiovaskularnih dogodkov pri dislipidemični populaciji z rezidualnim tveganjem |
| CA3065295C (fr) | 2017-06-01 | 2023-08-29 | Eli Lilly And Company | Dulaglutide pour le traitement de maladies renales chroniques |
-
2019
- 2019-09-25 CA CA3177693A patent/CA3177693A1/fr active Pending
- 2019-09-25 CA CA3056663A patent/CA3056663C/fr active Active
- 2019-10-31 TW TW114108702A patent/TW202525321A/zh unknown
- 2019-10-31 TW TW112117900A patent/TWI880215B/zh active
- 2019-10-31 TW TW108139459A patent/TWI804692B/zh active
- 2019-11-04 CN CN202210427909.XA patent/CN114732897A/zh active Pending
- 2019-11-04 KR KR1020247041950A patent/KR20250005518A/ko active Pending
- 2019-11-04 EA EA202192296A patent/EA202192296A1/ru unknown
- 2019-11-04 AU AU2019439626A patent/AU2019439626B2/en active Active
- 2019-11-04 EP EP19812886.0A patent/EP3946428A1/fr active Pending
- 2019-11-04 IL IL325089A patent/IL325089A/en unknown
- 2019-11-04 UA UAA202105390A patent/UA128791C2/uk unknown
- 2019-11-04 KR KR1020217031248A patent/KR102745779B1/ko active Active
- 2019-11-04 US US17/599,621 patent/US11890325B2/en active Active
- 2019-11-04 KR KR1020237030298A patent/KR20230132627A/ko not_active Ceased
- 2019-11-04 SG SG11202109892U patent/SG11202109892UA/en unknown
- 2019-11-04 MA MA055467A patent/MA55467A/fr unknown
- 2019-11-04 CN CN202411808628.4A patent/CN119564834A/zh active Pending
- 2019-11-04 CN CN201980095007.7A patent/CN113631181A/zh active Pending
- 2019-11-04 MX MX2021012177A patent/MX2021012177A/es unknown
- 2019-11-04 WO PCT/US2019/059631 patent/WO2020204998A1/fr not_active Ceased
- 2019-11-04 BR BR112021017315A patent/BR112021017315A2/pt not_active Application Discontinuation
-
2021
- 2021-08-22 IL IL285765A patent/IL285765A/en unknown
- 2021-08-27 ZA ZA2021/06250A patent/ZA202106250B/en unknown
-
2022
- 2022-12-30 AU AU2022291679A patent/AU2022291679B2/en active Active
-
2024
- 2024-01-10 US US18/409,277 patent/US20240139287A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230132627A (ko) | 2023-09-15 |
| KR20250005518A (ko) | 2025-01-09 |
| CN119564834A (zh) | 2025-03-07 |
| CN114732897A (zh) | 2022-07-12 |
| AU2019439626B2 (en) | 2022-10-13 |
| WO2020204998A1 (fr) | 2020-10-08 |
| US20220202908A1 (en) | 2022-06-30 |
| SG11202109892UA (en) | 2021-10-28 |
| AU2022291679B2 (en) | 2026-02-05 |
| US11890325B2 (en) | 2024-02-06 |
| US20240139287A1 (en) | 2024-05-02 |
| AU2022291679A1 (en) | 2023-02-02 |
| ZA202106250B (en) | 2023-04-26 |
| TW202103729A (zh) | 2021-02-01 |
| BR112021017315A2 (pt) | 2021-11-16 |
| CA3177693A1 (fr) | 2020-10-05 |
| MX2021012177A (es) | 2021-11-04 |
| UA128791C2 (uk) | 2024-10-23 |
| IL285765A (en) | 2021-10-31 |
| CN113631181A (zh) | 2021-11-09 |
| KR20210134713A (ko) | 2021-11-10 |
| CA3056663C (fr) | 2022-10-18 |
| TW202400213A (zh) | 2024-01-01 |
| CA3056663A1 (fr) | 2020-10-05 |
| IL325089A (en) | 2026-02-01 |
| KR102745779B1 (ko) | 2024-12-26 |
| TW202525321A (zh) | 2025-07-01 |
| EA202192296A1 (ru) | 2022-01-21 |
| AU2019439626A1 (en) | 2021-09-16 |
| TWI880215B (zh) | 2025-04-11 |
| TWI804692B (zh) | 2023-06-11 |
| EP3946428A1 (fr) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| KR102199943B9 (ko) | 의료용 자극 장치 | |
| IL285771A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| LT4331584T (lt) | Lanifibranoro deuterintų darinių terapietiniai naudojimai | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| DK3740504T3 (da) | CD70 kombinationsterapi | |
| DK3612624T3 (da) | Genterapi | |
| PT3645518T (pt) | Síntese de omecamtiv mecarbil | |
| IL287904A (en) | Combination treatment of arthritic disease | |
| PL3346995T3 (pl) | Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności | |
| EP3735463A4 (fr) | Agent thérapeutique induisant une cytotoxicité | |
| MA43270A (fr) | Inhibiteur de la c1 estérase humaine recombinante et ses utilisations | |
| LT3576740T (lt) | Vėžio gydymas | |
| EP3774737A4 (fr) | Modulateurs de calpaïne et leurs utilisations thérapeutiques | |
| EP3781179A4 (fr) | Enzymes kinuréninases humaines et utilisations associées | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| EP4041274A4 (fr) | Utilisations de ws-635 en médecine | |
| IL280968A (en) | Combination therapy | |
| EP3645003A4 (fr) | Association, utilisations et schémas thérapeutiques | |
| IL289338A (en) | Therapeutic interactions of leucomethylthioninium | |
| EP3752113C0 (fr) | Gaze chirurgicale | |
| IL290747A (en) | Therapeutic conjugate | |
| IL288237A (en) | Combination therapy | |
| IL285119A (en) | Use of spiropidion |